Basilea Pharma: FDA Allows To Proceed With Phase 1 Study For BAL0891
17/12 08:17
(RTTNews) - Basilea Pharmaceutica Ltd. (BPMUF.PK) announced the FDA has approved the company's Investigational New Drug application for the kinase inhibitor BAL0891. This allows the company to initiate the phase 1 clinical study in the first quarter of 2022. The IND approval trig...